Drug · DIN 02419475
REMDANTRY
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 12, 2025; first marketed September 4, 2014.
- Drug Identification Number (DIN)
- 02419475
- Company (DIN owner)
- Celltrion Inc.Incheon, --, Korea, Republic Of
- Schedule
- Prescription; Schedule d
- Dosage form
- Powder For Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Infliximab L04AB02
- Class
- Human
- Record last updated
- September 23, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| INFLIXIMAB | 100 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 4, 2024: NOC 34034New Drug Submission (NDS) · Administrative - Change in Product Ownership
- June 4, 2014: NOC 15665New Drug Submission (NDS) · Transfer of drug identification number
- January 15, 2014: NOC 15126New Drug Submission (NDS)